Key result
Various therapies including neurohormonal agents, dexrazoxane, statins, and aerobic exercise show potential in preventing and treating anthracycline-induced cardiotoxicity.
Why the study?
Current treatments for anthracycline-induced cardiotoxicity are largely extrapolated from conventional heart failure, highlighting the need for therapies specific to this condition as cancer survivorship improves.
What are the current and future therapeutic options for anthracycline-induced cardiotoxicity?
Design
Review
Authors
Loading...
Existing evidence supports neurohormonal agents, dexrazoxane, and resynchronization for AIC; leaves open validation of gene and stem cell therapies.
What are the current and future therapeutic options for anthracycline-induced cardiotoxicity?
This review highlights the evolving landscape of treatments for anthracycline-induced cardiotoxicity, ranging from conventional heart failure therapies to novel mechanism-specific targets.
Vuong et al. (2022) conducted a review in Anthracycline Induced Cardiotoxicity. Cardioprotective therapies (neurohormonal agents, dexrazoxane, statins, exercise) was evaluated. Various therapies including neurohormonal agents, dexrazoxane, statins, and aerobic exercise show potential in preventing and treating anthracycline-induced cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: